Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015569 citationsJournal Articlebronze Open Access

Authors

Nicholas Butowski · UCLA Medical Center

Howard Colman · University of California, San Francisco

John de Groot · The University of Texas MD Anderson Cancer Center

Antonio Omuro · Brigham and Women's Hospital

Lakshmi Nayak · Memorial Sloan Kettering Cancer Center

Patrick Y. Wen · The University of Texas MD Anderson Cancer Center

Timothy F. Cloughesy

Abstract

PLX3397 was well tolerated and readily crossed the blood-tumor barrier but showed no efficacy. Additional studies are ongoing, testing combination strategies and potential biomarkers to identify patients with greater likelihood of response.

Topics & Keywords

Glioma Diagnosis and Treatment Neuroinflammation and Neurodegeneration Mechanisms Immune cells in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuro-Oncology

Volume 18, Issue 4, pp. 557-564

DOI: 10.1093/neuonc/nov245

Field-Weighted Citation Impact: 14.89